VACCINE INVESTMENT STRATEGY 2024: PROPOSED SHORTLIST

BOARD MEETING
Marta Tufet
Kelechi Ohiri

6-7 December 2023, Accra, Ghana

gavi.org
Analytical and consultative process with 3 decisions

1. WHO vaccine landscape analysis
2. VIS candidate longlist
3. Evaluation framework
4. Vaccine analyses
5. Prioritisation methodology
6. Vaccine shortlist
7. Refined analyses
8. Investment Cases
# VIS 2024 longlisted vaccines

The table below summarizes the existing portfolio and the longlisted vaccines for VIS 2024:

<table>
<thead>
<tr>
<th>Existing portfolio</th>
<th>VIS 2018 vaccines</th>
<th>VIS 2024 vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergency Stockpiles</td>
<td></td>
<td>GBS, COVID-19*</td>
</tr>
<tr>
<td>Pregnant women</td>
<td></td>
<td>Shigella</td>
</tr>
<tr>
<td>Newborns (&lt;12 months)</td>
<td></td>
<td>Dengue</td>
</tr>
<tr>
<td>Infants (1-2 years)</td>
<td></td>
<td>TB</td>
</tr>
<tr>
<td>2nd year of life (13-23 month)</td>
<td></td>
<td>COVID-19</td>
</tr>
<tr>
<td>Older children (2-8 years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adolescents (9-19 years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adults</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Older people</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health workers</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Pending further review of WHO COVID-19 Vaccine Roadmap
Proposed vaccine shortlist

Endemic disease prevention

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Total Points (out of 100)</th>
<th>Quantitative ranking criteria</th>
<th>Qualitative ranking criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB</td>
<td>88 (incl. MICs = 88)</td>
<td>40% Health impact</td>
<td>20% Equity</td>
</tr>
<tr>
<td>Group B Strep</td>
<td>71 (incl. MICs = 71)</td>
<td>20% Value for money</td>
<td>10% Gavi comparative advantage</td>
</tr>
<tr>
<td>Shigella</td>
<td>43 (incl. MICs = 43)</td>
<td>10% Economic impact</td>
<td></td>
</tr>
<tr>
<td>Dengue</td>
<td>25 (incl. MICs = 28)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Epidemic disease prevention

Hepatitis E

Chikungunya

Mpox

COVID-19 from 2026, time-limited

Modulating criteria informed shortlist

- AMR
- Climate change
- Implementation feasibility
- Broader health system impact
- Global agenda

Board Meeting, 6-7 December 2023
VIS 2024 impact comparable to current portfolio

DALYs averted per 100K vaccinated

Deaths averted per 100K vaccinated

TB (+MICs 45)  TB (Gavi 55)  COVID-19*  GBS  Shigella  Dengue (+MICs 45)  Dengue (Gavi 55)  Pentavalent  HPV  PCV  Measles (MCV 2)  YF  Rota  MenA  Typhoid  Rubella  JE  Cholera

DALY estimates for COVID-19 are currently not available, in this instance YLL is being used for a comparator as evidence suggests YLLs account for >95% of DALYs for the majority of vaccine preventable diseases.

Vaccine impact for current Gavi portfolio vaccines is based on Gavi operational forecasting version 20 (2022-2030). Vaccine impact for VIS candidate vaccines (2026-2040), COVID-19 (2026-2023)

Source: External modellers, Gavi portfolio data
Recommendation

The Gavi Alliance Programme and Policy Committee **recommends** to the Board that it:

For vaccines for endemic disease prevention:

a) **Request** the Secretariat to develop possible investment options for further consideration for tuberculosis, group B streptococcus, shigella and dengue vaccines;

For vaccines for epidemic-prone diseases:

b) **Request** the Secretariat to develop possible investment options for further consideration for hepatitis E vaccines;

c) **Request** the Secretariat to monitor and update living assessments for Chikungunya and Mpox vaccines, including potential investments in learning agendas in consultation with WHO and other partners, and;

For COVID-19 from 2026:

d) **Request** the Secretariat to develop possible investment options for further consideration of a continued time-limited COVID-19 vaccine programme from 2026.

**Next steps:** refined analyses, detailed costing and continuous consultations to develop investment cases and learning agendas for final decision in June 2024.
Thank you